Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

3.39
-0.0259-0.76%
Volume:517.48K
Turnover:1.78M
Market Cap:416.94M
PE:-3.73
High:3.48
Open:3.43
Low:3.38
Close:3.42
52wk High:5.17
52wk Low:1.69
Shares:123.03M
Float Shares:94.52M
Volume Ratio:0.38
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9085
EPS(LYR):-1.2666
ROE:-48.14%
ROA:-19.25%
PB:1.69
PE(LYR):-2.68

Loading ...

Jan 11, 2024

Major Issues Report

Form 8-K - Current report
Jan 10, 2024

Major Issues Report

Form 8-K - Current report
Jan 05, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 26, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 22, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Dec 12, 2023

Major Issues Report

Form 8-K - Current report
Dec 12, 2023

Major Issues Report

Form 8-K - Current report
Nov 20, 2023

Major Issues Report

Form 8-K - Current report
Nov 14, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 01, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 01, 2023

Major Issues Report

Form 8-K - Current report
Sep 05, 2023

Major Issues Report

Form 8-K - Current report
Aug 08, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 08, 2023

Major Issues Report

Form 8-K - Current report
Jul 25, 2023

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 20, 2023

Major Issues Report

Form 8-K - Current report
Jun 12, 2023

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
May 30, 2023

Major Issues Report

Form 8-K - Current report
May 04, 2023

Major Issues Report

8-K - Current report
May 04, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]